Social Media Ideas for Pharma Patents

<![CDATA[Inside Pharma's Patent Battleground: The Policy Changes Reshaping Generic and Biosimilar Competition]]>

<![CDATA[A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims]]>

Practical Guidance for Pharmaceutical Method-of-Use Patent Claims After Teva v. Eli Lilly and In re Xencor

One Atomic Substitution, Two Giant Hurdles of Disclosure and Efficacy

In Intra Cellular Therapies v. Controller of Patents, the Delhi High Court revisited two recurring fault lines in pharmaceutical patent law: the coverage disclosure distinction in...

Mavyret Patent Abandonment Does Not Open the Field for Hepatitis C Generics

July 28, 2026 marked eight years of the National Viral Hepatitis Control Program (NVHCP). Launched under the National Health Mission, the program aims to eliminate Hepatitis C from...

Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the K...

Protecting Biotech Innovation In The Platform Knowledge Era

Following the U.S. Food and Drug Administration's recent shift toward leveraging prior and platform knowledge in biotechnology, companies should protect their innovations by guardi...

Turning CPG Supply Chain Pain Into Patent Gain

CPG companies are discovering that the manufacturing innovations required to work with natural ingredients may be patentable.

Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech

Sanofi's pharmaceutical and therapeutics subsidiaries say the COVID-19 vaccines that have netted Pfizer and Moderna billions of dollars infringe their patents covering mRNA technol...

Comments on CDSCO’s Brand Name Extension Policies

Earlier this month, we had shared the news of CDSCO inviting comments on the long standing problem of Brand Name Extensions (BNE) practices. While this problem is one with severe c...

Mid-Year Updates in the Pharmaceutical and Healthcare Industry

SpicyIP Tidbit: CGPDTM Calls for Comments and Suggestions on New Draft Pharma and Biotech Patent Application Guidelines...

In the time of this oncoming monsoon, it feels like its raining draft guidelines from the Controller General’s office! The office of the Controller General of Patents, Designs and...

Godavari Biorefineries secures European patent for anti-cancer pharmaceutical composition

The patent strengthens the company’s oncology-focused intellectual property portfolio and supports its efforts to develop potential healthcare applications through formulation rese...

Part II: To CL Or Not To CL: That Ought Not Be The Question

Continuing from Part I, Rishabh Upadhyay explains that making a patented medicine free on paper does not necessarily make it accessible in practice. Through Rajasthan’s procurement...

Sandoz Generic Would Infringe J&J Unit Patents, Judge Says

A New Jersey federal judge has ruled that Sandoz's attempt to manufacture a generic form of a Janssen Pharmaceuticals Inc. nasal spray would infringe a group of patents the Johnson...

<![CDATA[What FDA's Peptide Decision Means for the Industry]]>

<![CDATA[The Path from Discovery to Global Commercialization]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Pasatru]]>

USPTO Leaders Reinstate Double Patenting Ax In Sanofi Case

A panel including U.S. Patent and Trademark Office Director John Squires ruled Thursday that a Sanofi patent application must be rejected for double patenting, but questioned wheth...

Pfizer vs. Johnson & Johnson: Which Pharma Giant Is Better Prepared for Its Patent Cliff?

CAFC Affirms PTAB Denial of Motions to Amend Remaining Pfizer Claims Invalidated by Sanofi

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Friday affirmed a Patent Trial and Appeal Board (PTAB) decision denying Pfizer’s motions to amend two patent claims. Thi...

<![CDATA[The Shift Towards Globally Sourced Innovation]]>

Biotech deals surge to record as fear of missing out grips Big Pharma

Prospect of patents expiring on lucrative drugs prompts drugmakers to hunt for next blockbuster medicines

Fed. Circ. Upholds Block On MSN Cancer Drug In Exelixis Win

The Federal Circuit on Monday rejected MSN Laboratories' argument that three Exelixis patents on the blockbuster cancer drug Cabometyx are invalid, while dismissing as moot an appe...